35212-96-5

Basic information

• Product Name: METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE
• Synonyms: METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE;Methyl 5-chlorobenzo[b]thiophene-2-carboxylate;5-CHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID METHYL ESTER;Benzo[b]thiophene-2-carboxylic acid, 5-chloro-, methyl ester;Methyl 5-Chloro-1-Benzothiophene-2-Carboxylate(WXC03947)
• CAS NO: 35212-96-5
• Molecular Formula: C10H7ClO2S
• Molecular Weight: 226.67938
• Mol File: 35212-96-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 113-115
• Boiling Point: 338.7 °C at 760 mmHg
• Flash Point: 158.6 °C
• Appearance: /
• Density: 1.391 g/cm³
• Vapor Pressure: 9.66E-05mmHg at 25°C
• Refractive Index: 1.646
• CAS DataBase Reference: METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE(35212-96-5)
• EPA Substance Registry System: METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE(35212-96-5)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 35212-96-5(Hazardous Substances Data)

Usage

Description

METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE is an organic compound with the chemical structure of a methyl ester derivative of 5-chloro-1-benzothiophene-2-carboxylic acid. It is characterized by its potential applications in the pharmaceutical and chemical industries due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE is used as a reagent for the synthesis of various bioactive compounds, specifically amide-, urea-, and thiourea-functionalized dipeptides. These dipeptides serve as selective linear tachykinin NK2 receptor antagonists, which have potential applications in treating various conditions related to the tachykinin receptor system.
Additionally, METHYL 5-CHLORO-1-BENZOTHIOPHENE-2-CARBOXYLATE is used in the preparation of benzothiophene carboxamides, which are known as urotensin-II receptor antagonists. These compounds have potential therapeutic applications in treating cardiovascular and cerebrovascular diseases, as well as other conditions related to the urotensin-II receptor system.

InChI:InChI=1/C10H7ClO2S/c1-13-10(12)9-5-6-4-7(11)2-3-8(6)14-9/h2-5H,1H3

Upstream product

• 6628-86-0 5-chloro-2-nitrobenzaldehyde 
• 2365-48-2 Methyl thioglycolate 
• 96515-79-6 5-chloro-2-fluorobenzaldehyde 
• 20532-33-6 5-chlorobenzothiophene 
• 124-38-9 carbon dioxide 
• 74-88-4 methyl iodide 

Downstream Products

• 13771-75-0 5-chloro-benzo(b)thiophene-2-carboxylic acid 
• 13771-71-6 2-Hydroxymethyl-5-chlor-benzothiophen 

Relevant articles and documents

Design, synthesis, and biological activity evaluation of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives as broad-spectrum antifungal agents

To discover antifungal compounds with broad-spectrum and stable metabolism, a series of 2-(benzo[b]thiophen-2-yl)-4-phenyl-4,5-dihydrooxazole derivatives was designed and synthesized. Compounds A30-A34 exhibited excellent broad-spectrum antifungal activity against Candida albicans with MIC values in the range of 0.03–0.5 μg/mL, and against Cryptococcus neoformans and Aspergillus fumigatus with MIC values in the range of 0.25–2 μg/mL. In addition, compounds A31 and A33 showed high metabolic stability in human liver microsomes in vitro, with the half-life of 80.5 min and 69.4 min, respectively. Moreover, compounds A31 and A33 showed weak or almost no inhibitory effect on the CYP3A4 and CYP2D6. The pharmacokinetic evaluation in SD rats showed that compound A31 had suitable pharmacokinetic properties and was worthy of further study.

Direct Carboxylation of Electron-Rich Heteroarenes Promoted by LiO-tBu with CsF and [18]Crown-6

We herein demonstrate that the combination of LiO-tBu, CsF, and [18]crown-6 efficiently promotes the direct C?H carboxylation of electron-rich heteroarenes (benzothiophene, thiophene, benzofuran, and furan derivatives). A variety of functional groups, including methyl, methoxy, halo, cyano, amide, and keto moieties, are compatible with this system. The reaction proceeds via the formation of a tert-butyl carbonate species.

GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.